A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.

Sevinsky, Heather; Tao, Xiaolu; Wang, Reena; Ravindran, Palanikumar; Sims, Karen; Xu, Xiaohui; Jariwala, Navin; Bertz, Richard

Sevinsky, Heather; Tao, Xiaolu; Wang, Reena; Ravindran, Palanikumar; Sims, Karen; Xu, Xiaohui; Jariwala, Navin; Bertz, Richard.

Affiliation

Sevinsky H; Research and Development, Bristol-Myers Squibb, Pennington, NJ, USA. heather.sevinsky@bms.com.

Antivir Ther ; 20(5): 493-500, 2015.

Article in En | MEDLINE | ID: mdl-25361436

Subject(s)

Atazanavir Sulfate/pharmacokinetics; Cobicistat/pharmacokinetics; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics; HIV Protease Inhibitors/pharmacokinetics; Administration, Oral; Adolescent; Adult; Biological Availability; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections/drug therapy; Healthy Volunteers; Humans; Male; Middle Aged; Therapeutic Equivalency; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Protease Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cobicistat / Atazanavir Sulfate Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Antivir Ther Journal subject: TERAPIA POR MEDICAMENTOS / VIROLOGIA Year: 2015 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google